Vol. 18/No. 08

As the population of cancer survivors has grown, so has the risk that patients will develop— and succumb to—a second cancer.

As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.

The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.

A panel of experts discusses standard treatments for early-stage and advanced liver cancer, reviews investigational second-line therapies, and expresses optimism that some of these therapies may one day improve outcomes for patients.

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.

Research on a scalp-cooling device to help patients with breast cancer avoid hair loss during chemotherapy illustrates this question: what level of evidence might individual clinicians require before they would suggest, recommend, or support the use of a particular approach in treating patients outside the realm of the mandates of governmental agencies or payers?

Survivorship care for patients who have had cancer is a relatively new phenomenon in the oncology field. After all, the transformation of many cancers from fatal to chronic conditions has occurred in less than a decade. Not surprisingly, then, the science of survivorship care is still evolving, too.